Varenicline and Alcohol in Inpatient Addictions Program (IAP)
Stopped early · Phase 3
Conditions studied: Alcoholism, Nicotine Dependence
In brief
The overall hypothesis of this line of research is that varenicline will decrease alcohol consumption and tobacco use and will increase alcohol and tobacco abstinence rates. In order to explore this hypothesis, the investigators will conduct a two-phase study: 1) an open label pilot study investigating the effect of varenicline on reduction of and abstinence from alcohol and tobacco; and 2) an optional MR spectroscopy to investigate whether glutamate and other brain metabolites correlate to measures of alcohol craving severity and/or subsequent varenicline treatment response.
Key facts
- Study ID
- NCT01169610
- Run by
- Mayo Clinic
- People needed
- 1
- Starts
- 2011-01-01
- Expected to finish
- 2013-06-01
- Last updated by the study team
- 2019-03-20
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.